AUROPHARMA jumped +4.4% on a box breakout
Aurobindo Pharma ended the session 4.36% higher at ₹1,717.00, closing at the day's high and at a fresh 52-week high. The stock opened with a 0.2% gap-up, rose from its previous close of ₹1,645.30, and traded across a ₹1,635.10–₹1,717.00 band, while the Nifty slipped just 0.04%, so the strength was stock-specific.
The tape was convincing. Volume ran 4.5x its normal level, the price held 1.81% above its VWAP, and the stock's futures traded at a 1.02% premium to spot — a bullish tick in the derivatives shelf. On the charts Aurobindo triggered a Darvas breakout and is sitting above both its 50- and 200-day averages, with the 14-day RSI at 68.9 and relative volume of 2.43.
The momentum readings are striking. Over the past week the stock is up 6.778% and over the past month 8.657%, and it is 68.98% above its 52-week low. A report from Business Standard noted the stock had spurts 3.36% and was gaining for a fifth straight session, while Univest flagged the fresh 52-week high.
The news backdrop is earnings-led. Reuters reported that Aurobindo posted a quarterly profit rise on anti-retroviral drug demand, and GuruFocus recapped a Q1 2027 earnings call highlighting record revenue growth. A separate note from Simply Wall St pointed to a modest fair-value lift as analysts reworked their assumptions. There was no negative headline in the pack to counter the move.
What the data establishes is a clean breakout to a 52-week high on strong volume and a positive earnings narrative, with the futures premium confirming the tone. What it does not establish is how much further the run extends — at a 52-week high with the RSI near 69, the stock is extended, and the data shows no fresh catalyst beyond the earnings and re-rating already in the price.
The numbers
- Last price ₹1,717.00, +4.36% on the day
- Day range ₹1,635.10 – ₹1,717.00
- Opening gap +0.20%
- NIFTY moved -0.04% the same session
Signals that fired
- Volume spike 4.5x
- At day's high
- Futures premium +1.02%
- Above VWAP +1.81%
Technical context
Volume ran at 2.4× its 20-day average; rsi(14) sits at 69; price is 0.0% from the 52-week high; trading above the 50-dma and 200-dma.
Recent headlines
- Aurobindo Pharma Ltd spurts 3.36%, gains for fifth straight session — Business Standard (1h ago)
- Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Modest Fair Value Lift On Revised Assumptions — Simply Wall St. (10d ago)
- Aurobindo Pharma shares slip after opening higher; here is why — Business Today (17d ago)
- Aurobindo Pharma Ltd. Share Price at Fresh 52-Week High — Univest (18d ago)
- Aurobindo Pharma Ltd (BOM:524804) (Q1 2027) Earnings Call Highlights: Record Revenue Growth and ... — GuruFocus.com (24d ago)
- Stock Picks Today: Cummins, Berger Paints, Aurobindo Pharma, Hindalco Novelis, Metropolis, And More On Brokerages' Radar — NDTV Profit (25d ago)
- Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Modest Fair Value Lift As Analysts Rework Assumptions — Simply Wall St. (25d ago)
- India's Aurobindo Pharma posts quarterly profit rise on anti-retroviral drug demand — Reuters (25d ago)
Sources
- Aurobindo Pharma Ltd spurts 3.36%, gains for fifth straight session — Business Standard
- Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Modest Fair Value Lift On Revised Assumptions — Simply Wall St.
- Aurobindo Pharma shares slip after opening higher; here is why — Business Today
- Aurobindo Pharma Ltd. Share Price at Fresh 52-Week High — Univest
- Aurobindo Pharma Ltd (BOM:524804) (Q1 2027) Earnings Call Highlights: Record Revenue Growth and ... — GuruFocus.com
- Stock Picks Today: Cummins, Berger Paints, Aurobindo Pharma, Hindalco Novelis, Metropolis, And More On Brokerages' Radar — NDTV Profit
- Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Modest Fair Value Lift As Analysts Rework Assumptions — Simply Wall St.
- India's Aurobindo Pharma posts quarterly profit rise on anti-retroviral drug demand — Reuters
Keep digging
- AUROPHARMA — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.